Physician profile
Howard Goldsmith
NPI 1972603561
$5,859.92
in general payments reported to CMS, 2019-2025
30 companies · $465 in 2025
The $465 reported for 2025 was more than what a typical Foot & Ankle Surgery provider received nationally (typical 2025 total: $424).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,281 · 2020: $745 · 2021: $472 · 2022: $1,686 · 2023: $121 · 2024: $90.26 · 2025: $465.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $676.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $676.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gotham Surgical Solutions & Devices, INC. | $1,200.00 | 2022 | |
| Horizon Therapeutics Plc | $1,143.62 | 2019-2023 | Krystexxa |
| Abbott Laboratories | $542.59 | 2019-2020 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $348.94 | 2019-2024 | Jublia |
| Bolton Medical INC | $294.67 | 2019 | |
| Smith+Nephew, INC. | $267.44 | 2019-2022 | |
| Abbvie INC. | $246.23 | 2019 | |
| Merck Sharp & Dohme LLC | $239.14 | 2019 | |
| Bioventus LLC | $238.36 | 2022-2025 | Exogen Ultrasound Bone Healing System |
| Stryker Corporation | $170.54 | 2025 | Hoffmann |
| Paratek Pharmaceuticals, INC. | $166.81 | 2020-2023 | Nuzyra |
| Amgen INC. | $141.97 | 2024-2025 | Krystexxa |
| Osiris Therapeutics INC. | $124.61 | 2019 | |
| Medtronic Vascular, INC. | $121.18 | 2019 | |
| Celularity INC. | $111.94 | 2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $62.61 | 2022 | |
| Acell, INC. | $54.89 | 2019 | |
| Orthofix Medical, INC. | $50.64 | 2019-2022 | |
| Integra Lifesciences Corporation | $41.21 | 2019 | |
| Organogenesis INC. | $39.60 | 2019-2022 | |
| Zimmer Biomet Holdings, INC. | $39.38 | 2021 | |
| Nabriva Therapeutics, Plc | $35.66 | 2020-2021 | |
| Melinta Therapeutics, LLC | $34.71 | 2019 | |
| Royal Biologics, INC. | $30.24 | 2019 | |
| Kerecis Limited | $24.69 | 2023 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Omega3 Graftguide |
| Sebela Pharmaceuticals INC. | $24.19 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $16.89 | 2022 | |
| Tactile Systems Technology INC | $16.88 | 2022 | |
| Hartmann USA, INC. | $15.86 | 2022 | |
| Misonix INC | $14.43 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Goldsmith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.